Highlight
– In the international, double-blind VESALIUS-CV trial, evolocumab reduced the risk of first major adverse cardiovascular events (3‑point MACE) by 25% versus placebo (HR 0.75; 95% CI 0.65–0.86) over a median 4.6 years.
– Absolute risk reductions were modest: 5‑year Kaplan–Meier estimates were 6.2% with evolocumab vs 8.0% with placebo for 3‑point MACE (absolute risk reduction ~1.8%; NNT ≈56 over 5 years) and 13.4% vs 16.2% for 4‑point MACE (ARR ~2.8%; NNT ≈36).
